1194 related articles for article (PubMed ID: 26184867)
1. How to define valvular atrial fibrillation?
Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
[TBL] [Abstract][Full Text] [Related]
2. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves.
Yadlapati A; Groh C; Malaisrie SC; Gajjar M; Kruse J; Meyers S; Passman R
Clin Res Cardiol; 2016 Mar; 105(3):268-72. PubMed ID: 26384981
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
[TBL] [Abstract][Full Text] [Related]
7. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
[TBL] [Abstract][Full Text] [Related]
8. [Antithrombotic treatment of patients with valvular atrial fibrillation].
Bovin A; Christensen TD; Grove EL
Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
[TBL] [Abstract][Full Text] [Related]
9. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
[TBL] [Abstract][Full Text] [Related]
10. Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study.
Furukawa Y; Miyake M; Fujita T; Koyama T; Takegami M; Kimura T; Sugio K; Takita A; Nishimura K; Izumi C;
Cardiovasc Drugs Ther; 2020 Oct; 34(5):689-696. PubMed ID: 32710129
[TBL] [Abstract][Full Text] [Related]
11. Defining nonvalvular atrial fibrillation: A quest for clarification.
Martins RP; Galand V; Colette E; Behar N; Pavin D; Leclercq C; Daubert JC; Mabo P
Am Heart J; 2016 Aug; 178():161-7. PubMed ID: 27502864
[TBL] [Abstract][Full Text] [Related]
12. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
[TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Di Pasquale G; Zagnoni S; Riva L
Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
[TBL] [Abstract][Full Text] [Related]
14. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Salem DN; Stein PD; Al-Ahmad A; Bussey HI; Horstkotte D; Miller N; Pauker SG
Chest; 2004 Sep; 126(3 Suppl):457S-482S. PubMed ID: 15383481
[TBL] [Abstract][Full Text] [Related]
16. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
18. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
19. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?
Aimo A; Giugliano RP; De Caterina R
Circulation; 2018 Sep; 138(13):1356-1365. PubMed ID: 30354416
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
Owens RE; Kabra R; Oliphant CS
Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
